CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.

ABSTRACT: Immunotherapy with CD123-specific T-cell engager proteins or with T cells expressing CD123-specific chimeric antigen receptors is actively being pursued for acute myeloid leukemia. T cells secreting bispecific engager molecules (ENG-T cells) may present a promising alternative to these approaches. To evaluate therapeutic potential, we generated T cells to secrete CD123/CD3-bispecific engager molecules. CD123-ENG T cells recognized primary acute myeloid leukemia (AML) cells and cell lines in an antigen-dependent manner as judged by cytokine production and/or tumor killing, and redirected bystander T cells to AML cells. Infusion of CD123-ENG T cells resulted in regression of AML in xenograft models conferring a significant survival advantage of treated mice in comparison to mice that receive

SUBMITTER: Bonifant CL 

PROVIDER: S-EPMC5113097 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature